Structure Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
148
- Stock Symbol
-
GPCR
- Share Price
-
$21.05
- (As of Friday Closing)
Structure Therapeutics General Information
Description
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
Contact Information
Website
www.structuretx.comCorporate Office
- 601 Gateway Boulevard
- Suite 900, South San Francisco
- San Francisco, CA 94080
- United States
Corporate Office
- 601 Gateway Boulevard
- Suite 900, South San Francisco
- San Francisco, CA 94080
- United States
Structure Therapeutics Timeline
Structure Therapeutics Stock Performance
As of 14-Mar-2025, Structure Therapeutics’s stock price is $21.05. Its current market cap is $1.21B with 57.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $21.05 | $20.40 | $19.39 - $62.74 | $1.21B | 57.3M | 869K | -$2.34 |
Structure Therapeutics Financials Summary
As of 31-Dec-2024, Structure Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 642,008 | 642,008 | 1,689,138 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (157,228) | (157,228) | (102,475) | (52,284) |
| Net Income | (122,526) | (122,526) | (89,620) | (51,321) |
| Total Assets | 903,330 | 903,330 | 482,017 | 97,845 |
| Total Debt | 3,862 | 3,862 | 5,453 | 260 |
Structure Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Structure Therapeutics Comparisons
Industry
Financing
Details
Structure Therapeutics Competitors (80)
One of Structure Therapeutics’s 80 competitors is Vertex Pharmaceuticals, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX | ||||
| Altimmune | Corporate Backed or Acquired | Gaithersburg, MD | ||||
| Regenacy Pharmaceuticals | Venture Capital-Backed | Waltham, MA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland |
Structure Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Structure Therapeutics Patents
Structure Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230391760-A1 | Heterocyclic glp-1 agonists | Pending | 13-Oct-2020 | ||
| US-20240083886-A1 | Heterocyclic glp-1 agonists | Pending | 13-Oct-2020 | ||
| US-20230331732-A1 | Heterocyclic glp-1 agonists | Pending | 10-Sep-2020 | ||
| US-20230071840-A1 | Heterocyclic glp-1 agonists | Inactive | 28-Aug-2020 | ||
| US-20230107793-A1 | Heterocyclic glp-1 agonists | Active | 28-Aug-2020 | C07D471/04 |
Structure Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Structure Therapeutics FAQs
-
When was Structure Therapeutics founded?
Structure Therapeutics was founded in 2016.
-
Where is Structure Therapeutics headquartered?
Structure Therapeutics is headquartered in San Francisco, CA.
-
What is the size of Structure Therapeutics?
Structure Therapeutics has 148 total employees.
-
What industry is Structure Therapeutics in?
Structure Therapeutics’s primary industry is Drug Discovery.
-
Is Structure Therapeutics a private or public company?
Structure Therapeutics is a Public company.
-
What is Structure Therapeutics’s stock symbol?
The ticker symbol for Structure Therapeutics is GPCR.
-
What is the current stock price of Structure Therapeutics?
As of 14-Mar-2025 the stock price of Structure Therapeutics is $21.05.
-
What is the current market cap of Structure Therapeutics?
The current market capitalization of Structure Therapeutics is $1.21B.
-
Who are Structure Therapeutics’s competitors?
Vertex Pharmaceuticals, Rein Therapeutics, Altimmune, Regenacy Pharmaceuticals, and CRISPR Therapeutics are some of the 80 competitors of Structure Therapeutics.
-
What is Structure Therapeutics’s annual earnings per share (EPS)?
Structure Therapeutics’s EPS for 12 months was -$2.34.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
